Lung NeoplasmsLUNG-ROLLNCT07143110
LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada
An observational study of Lung Neoplasms, run by AstraZeneca at 2 sites in Canada.
Trial summary
LUNG-ROLL is a retrospective cohort study that will describe the contemporary treatment patterns, prevalence and incidence, patient demographic and clinical characteristics, clinical outcomes, and healthcare resource use/costs for patients with lung cancer in Canada (specifically, Alberta and Ontario) using… Read more about this study
- Who is it for?
- Ages 18 to 130 years
- Conditions the study is for
- Lung Neoplasms
- How many people
- 60,000 participants
- Where
- 2 sitesCanada
- Study dates
- 20 Aug 2025to 30 Sep 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 130 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Study population will comprise patients with lung cancer diagnosed after January 1, 2018 in the administrative databases for Alberta and Ontario.
Who may be able to join
- Patients with lung cancer between January 1, 2018 and end of the Selection Period.
- Patient is 18 years of age or older on diagnosis date.
- Patient has at least 12 months of health insurance coverage prior to the diagnosis date.
Who cannot join
- Diagnosed with any other cancer in the 5-year period prior to January 1, 2018.
- Diagnosed with any other cancer concurrently (i.e., on the same date) as lung cancer diagnosis.
- Invalid or incomplete records for key variables (e.g., missing year of diagnosis, missing cancer type).
- Non-Ontario or non-Alberta resident on diagnosis date.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
AstraZeneca Clinical Study Information Center contact
Canada2 sites, 2 recruiting
- Recruiting
Research Site
Calgary, Alberta, T2N1N4
- Recruiting
Research Site
Toronto, Ontario, M5T3M6
About this study
LUNG-ROLL is a retrospective cohort study that will describe the contemporary treatment patterns, prevalence and incidence, patient demographic and clinical characteristics, clinical outcomes, and healthcare resource use/costs for patients with lung cancer in Canada (specifically, Alberta and Ontario) using administrative data.
- Conditions
- Lung Neoplasms
- Keywords
- Lung Neoplasms, Non-Small-Cell Lung, Small Cell Lung, Epidemiology, Treatment Patterns, Real-World
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Non-Small Cell Lung Cancer (NSCLC) | Not described | |
| Small Cell Lung Cancer (SCLC) | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Treatment patterns
Measured: Through study completion, an average of 1 year
Secondary outcomes (7)
Incidence and prevalence
Measured: Through study completion, an average of 1 year
Baseline demographic and clinical characteristics
Measured: Through study completion, an average of 1 year
Overall survival
Measured: Through study completion, an average of 6 months
Time to/on therapy
Measured: Through study completion, an average of 6 months
Attrition rates
Measured: Through study completion, an average of 1 year
Healthcare resource utilization (HCRU)
Measured: Through study completion, an average of 1 year
Direct healthcare costs
Measured: Through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Aug 2025
- Study start20 Aug 2025
- Primary completion30 Sep 2027 (estimated)
- Study completion30 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung NeoplasmsStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 60,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07143110
- Sponsor's protocol ID
- D133HR00044
- Acronym
- LUNG-ROLL
- Status last verified
- Sep 2026
- First submitted
- 30 May 2025
- Last updated
- 3 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada
- ClinicalTrials.gov ID
- NCT07143110
- Acronym / sponsor ID
- LUNG-ROLL / D133HR00044
- Conditions
- Lung Neoplasms
- Keywords
- Lung Neoplasms, Non-Small-Cell Lung, Small Cell Lung, Epidemiology, Treatment Patterns, Real-World
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 60,000 participants (estimated)
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Study start
- 20 Aug 2025 (actual)
- Primary completion
- 30 Sep 2027 (estimated)
- Study completion
- 30 Sep 2027 (estimated)
- First posted
- 27 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
LUNG-ROLL is a retrospective cohort study that will describe the contemporary treatment patterns, prevalence and incidence, patient demographic and clinical characteristics, clinical outcomes, and healthcare resource use/costs for patients with lung cancer in Canada (specifically, Alberta and Ontario) using administrative data.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Non-Small Cell Lung Cancer (NSCLC) | – | – |
| Small Cell Lung Cancer (SCLC) | – | – |
Who may qualify
- Ages
- 18 to 130 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Study population will comprise patients with lung cancer diagnosed after January 1, 2018 in the administrative databases for Alberta and Ontario.
Key inclusion criteria (3 listed)
- Patients with lung cancer between January 1, 2018 and end of the Selection Period.
- Patient is 18 years of age or older on diagnosis date.
- Patient has at least 12 months of health insurance coverage prior to the diagnosis date.
Key exclusion criteria (4 listed)
- Diagnosed with any other cancer in the 5-year period prior to January 1, 2018.
- Diagnosed with any other cancer concurrently (i.e., on the same date) as lung cancer diagnosis.
- Invalid or incomplete records for key variables (e.g., missing year of diagnosis, missing cancer type).
- Non-Ontario or non-Alberta resident on diagnosis date.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Treatment patterns
Time frame: Through study completion, an average of 1 year
7 secondary outcomes
Incidence and prevalence
Time frame: Through study completion, an average of 1 year
Baseline demographic and clinical characteristics
Time frame: Through study completion, an average of 1 year
Overall survival
Time frame: Through study completion, an average of 6 months
Time to/on therapy
Time frame: Through study completion, an average of 6 months
Attrition rates
Time frame: Through study completion, an average of 1 year
Healthcare resource utilization (HCRU)
Time frame: Through study completion, an average of 1 year
Direct healthcare costs
Time frame: Through study completion, an average of 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Lung Neoplasms
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
AstraZeneca Clinical Study Information Center contact
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Neoplasms, run by AstraZeneca at 2 sites in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact AstraZeneca Clinical Study Information Center (1-877-240-9479, information.center@astrazeneca.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Treatment patterns (time frame: Through study completion, an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2026.